Healthcare

SB 191 establishes a state-run pilot program for psychedelic-assisted therapy using MDMA and psilocybin, effective July 1, 2026. It directly affects qualified patients in Connecticut who are 18+ and meet specific criteria (veterans, retired first responders, or healthcare workers), providing them access to therapy administered by a state-selected medical school. The program requires federal FDA approval under 21 CFR 312 for research purposes and will terminate once MDMA/psilocybin receive DEA approval for medical use. The bill repeals an existing statute and creates a structured framework for this therapeutic pilot program.